Gamma Biosciences invests in Nirrin Technologies

By The Science Advisory Board staff writers

September 24, 2021 -- Gamma Biosciences has made an investment in bioprocessing firm Nirrin Technologies. Terms of the investment were not disclosed.

Gamma will provide support to Nirrin for helping expand customer engagement with the developer and manufacturers of cell and gene therapies, biologics, and vaccines, the company said.

Nirrin's bioprocessing platform uses near-infrared spectroscopy and back-end data processing for applications such as real-time glucose monitoring, cell density in-line measurements, and protein concentration and aggregation, according to Gamma Biosciences.

Gamma to acquire majority stake in Mirus Bio
Gamma Biosciences has purchased a controlling stake in Mirus Bio, a developer of lipid-polymer nanocomplexes for nucleic acid delivery.
Gamma Biosciences to acquire BioMagnetic Solutions
Gamma Biosciences has agreed to acquire BioMagnetic Solutions, a next-generation cell selection and bioseparation technology company.
Gamma announces Astrea, Avacta partnership
Life sciences firm Gamma Biosciences has announced a licensing agreement between chromatography developer Astrea Bioseparations and biotherapeutic and...
Gamma Biosciences acquires Nanopareil
Gamma Biosciences has purchased nanofiber membrane product developer Nanopareil.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter